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magnesium sulfate for an unknown reason is a huge accomplishment. We found the proximity of the
magnesium exposure to delivery to be on a very satisfying level. Altogether 68,0% of women gave
birth <12 hours after the exposure to MgSO4 had ceased, and as much as 58,4% delivered <6 hours
after the exposure to magnesium.
With 29,6% of those eligible for magnesium treatment, magnesium administration time was
miscalculated (maintenance dose shorter 30 minutes). This non-adherence to the local guidelines has
been noted and an auditing with midwives will be made. In conclusion, MgSO4 administration for
fetal neuroprotection has been successfully and safely implemented in our institution.
Avainsanat – Nyckelord – Keywords
Magnesium sulfate, neuroprotection, premature, proximity, bleeding, implementation, cerebral palsy
Säilytyspaikka – Förvaringställe – Where deposited
 E-thesis
Muita tietoja – Övriga uppgifter – Additional information
2Implementation of antenatal magnesium sulfate for fetal
neuroprotection in the third-level teaching university hospital
The retrospective analysis in period 2012-2016
Ritva Mettänen, LK
ritva.mettanen@helsinki.fi
Student no. 013862769
Thesis
Supervisor: Vedran Stefanovic
Adjunct Professor, Senior Consultant in Obstetrics, Gynecology and Fetal Medicine
HUCH Department of Obstetrics and Gynecology
Medical faculty, University of Helsinki
Helsinki 20/3/2017
31. Introduction ............................................................................................................ 3
1.1 Preterm Birth – Definition, Etiology, Morbidity ........................................................ 3
1.2 Use of Magnesium Sulfate in Obstetrics .................................................................. 4
1.3 Implementation of the New Guidelines .................................................................... 6
1.4 Implementation of Magnesium Sulfate in Department of Obstetrics and Gynecology,
Helsinki University Central Hospital (HUCH) ............................................................... 6
2. Objective of Research ............................................................................................ 7
3. Patients and Methods ............................................................................................. 7
4. Results ................................................................................................................... 8
5. Discussion ............................................................................................................ 13
6. Acknowledgements .............................................................................................. 14
7. References ............................................................................................................ 15
41. Introduction
1.1   Preterm Birth – Definition, Etiology, Morbidity
Premature birth is one that occurs at ≤ 36+6 weeks of gestation or less than 258 days of gestation.1
World Health Organization (WHO) classifies premature infants in three sub-categories by
gestational age: extremely preterm (< 28 weeks), very preterm (< 32 weeks) and moderate to late
preterm (32 to < 37 weeks).2
Altogether, there were 55759 children born in Finland in 2015. Of these 3316 were preterm birth
(5,9% of all deliveries, gestational age <37 weeks); 608 (1,09%) very or extremely prematurely
born. 1 The overall prevalence of preterm births in developed countries in 2010 was 8,3%.2
The major risk factors for a preterm birth are: multifetal pregnancy, intrauterine (intraamniotic)
infections (IAI), acute maternal infections, chronic maternal diseases with poor therapeutic
equilibrium, a previous preterm birth or miscarriage, history of cervical surgery, genital
malformations, a very young (< 18 years) or advanced (> 40 years) maternal age, lower
socioeconomic status, use of alcohol and drugs, smoking and antenatal bleeding.3
Most of the cases of preterm birth occurs as a spontaneous preterm labour with or without
premature rupture of membranes or as iatrogenic preterm delivery for various medical and
obstetrical indications (chorioamnionitis, severe intrauterine growth restriction with deteriorating
fetal status).
In a recently published research Raba et al. investigated a possibility to predict a preterm labor
within 7 days of enrollment by evaluating the predictive value for known risk factors, such as:
smoking before pregnancy, low socioeconomic status, frequent contractions during pregnancy,
bleeding during pregnancy and urinary tract infections in a cohort of 622 women hospitalized for
the threatened preterm labour. They found out that the accumulation of these five risk factors have
ability to predict a preterm labor within a week of enrollment with a positive predictive value of
98%.4
In addition to high risk of perinatal mortality, a very preterm infant has a major risk of developing
severe neurological problems, such as damage of developing brain, cerebral palsy, cognitive
dysfunction and cerebral hemorrhage. The risk decreases considerably after 32 gestational weeks.5
The risk for a very preterm child to develop cerebral palsy is significantly higher than for child born
at term or later than 32 weeks of gestation. For example in Australia and New Zealand of all the
patients diagnosed with cerebral palsy, 40% are related to preterm birth.6
Cerebral palsy (CP) is a syndrome which includes neurodevelopmental disabilities, such as
permanent defects in movement, postural maintenance and function. It is caused by a single damage
in developing brain in the area of motoric regulations. The brain is most commonly damaged during
fetal period, either during first trimester e.g. due to an infection or exposure to toxic items, or during
26 to 34 gestational weeks when the matter surrounding cerebral ventricles is most vulnerable.7
Another known cause of CP is hypoxic–ischemic encephalopathy (HIE). It is suggested that 14.5%
of children with CP would have been damaged by ischemia or hypoxia during labour at term.8
Additionally gastrointestinal and nutritional problems, orthopedic problems, sensory disabilities,
intellectual disabilities, trouble in cognition and behavior, limited life expectancy and epilepsy are
in some cases, depending on the size and precise spot of damage, associated with CP.7,8 In Finland
5100-120 children are diagnosed with CP each year possessing a significant burden to the children,
their families and the society.7 It is not only the most common syndrome which requires long term
and regular rehabilitation all through life, but it is also one of the most expensive syndromes for our
society.  In 2003 lifelong direct and indirect costs for a person with CP were estimated to be
US$921 000 per person.8 Approximately the same results were achieved by a Danish group or
researchers in 2008, where estimated costs rose up to 861 000€, with only 7.6% of this amount
related to the medical costs.9
1.2   Use of Magnesium Sulfate in Obstetrics
Magnesium sulfate (MgSO4) is widely used in obstetrics for three main indications: 1) prevention
and treatment of eclampsia-related seizures, 2) fetal neuroprotection and 3) tocolysis associated
with preterm labour. Rarely, the fetal intrauterine resuscitation during intrapartum distress may be
attempted by magnesium sulfate.10
MgS04 has been used for more than a century for pre-eclampsia-related seizures and prevention of
eclampsia and has been a drug of choice for this indication for decades with a reduction in maternal
deaths and reoccurrence of seizures.11 In RCT’s it has been proved to be a better anticonvulsive
drug than diazepam or phenytoin, wherefore it has already been used for a century and continues to
be used as a main drug in prevention and treatment of eclampsia.12
Since late 1960’s it has been known, that magnesium sulfate impairs myometrial contractility in
vitro. Therefore magnesium was introduced into clinical practice for decades as a tocolytic drug.
The initial enthusiasm has diminished after the first RCTs in mid 80´s that failed to prove the
effectiveness of MgSO4 as a tocolytic drug.12
Despite of the proven ineffectiveness of MgSO4 as a tocolytic (even in delaying labour for the short
time needed to administer corticosteroids),  still ten years ago almost 45% of obstetricians in the
United States still used it as the first-line tocolytic agent.13
In a retrospective study of a long-term burden of hypoxic-ischaemic encephalopathy, Eunson et al.
suggested, that continuous administration of magnesium sulfate for women with severe early-onset
preeclampsia would have a favourable effect in fetal outcome by postponing deterioration of
preeclampsia, alleviating decreasing maternal platelet count and prolonging pregnancy with
approximately 7 days.8 However, it is well-known that long-term infusion of magnesium sulfate has
several adverse effects, such as a higher incidence of pulmonary edema, an increasing proteinuria
and possible fetal and neonatal demineralization and fractures when administrated continuously for
more than a week. 8
The prognosis of preterm infants has markedly improved since 1992, when Kuban et al. found in
their research that maternal receipt of magnesium sulfate decreased the risk of germinal matrix
hemorrhage, even in infants born to mothers who did not evidently have preeclampsia.14
In 1995 Nelson et al. showed in their study that children who had been exposed to antenatal
magnesium sulfate had less cerebral palsy syndrome as in controls. Although their study consisted
only of children with very low birth weight (VLBW, <1500g) it was rather evident that magnesium
sulfate had a protective effect against CP.15
Doyle et al. published an updated systematic review of five RCT’s in 2009 in which they proved,
that antenatal magnesium sulfate administration markedly decreased the risk of cerebral palsy and
substantial gross motor dysfunction in preterm infants. There was no remarkable increase in major
maternal complications, but a little higher amount of maternal adverse effects, e.g. tachycardia and
hypotension was noted. Also no effect on other neurological impairments was found. 16
6These five trials (Table A) were included in a Cochrane systematic review, which confirmed
benefit, showing that 63 mothers need to be given magnesium sulfate prior to very preterm birth to
prevent one case of cerebral palsy.16 In a research of Magee et al. it was noted, that the NNT to
prevent 1 CP or death was 43 and NNT to prevent one CP only was 50 at 32 weeks of gestation.17
Study Country;
no. of location
centers;
no. of
countries;
no. of subjects
Inclusion No. of
infants
Regimen; initial
dose;
maintenance
CP RR (95% CI):
combined perinatal
death & CP RR
(95% CI)
MagNET
Mittendorf et
al.
US
1
1
149
25 – 33 weeks
PTL
165 4 g
2-3 g/hr*
Not significant (of
n=3 in both treated
and placebo group)
n/a
ACTO MgSO4
Crowther et al.
Australia
16
2
1062
< 30 weeks
Delivery
expected < 24
hrs
1255 4 g / 20 mins
1 g / hr (not to
exceed 24 hrs)
0.85 (0.56 – 1.31)
0.83 (0.66 – 1.03)
Magpie Trial
Duley et al.
International
125
19
1544
<37 weeks
Severe pre-
eclampsia
1593 4 g / 10-15 mins
1  g  /  hr  (for  24
hrs)
0.66 (0.11 – 3.94)
1.06 (0.09 – 1.25)
PREMAG
Marret et al.
France
13
1
573
< 33 weeks
PTL
688 4 g / 30 mins
No maintenance
0.70 (0.41 – 1.19)
0.86 (0.55 – 1.34)
BEAM
Rouse et al.
US
20
1
2241
24 – 31 weeks
High risk of
spontaneous
birth
2444 6g per 20-30
mins
2 g/hr (for 12
hrs)
0.59 (0.40 – 0.85)
0.97 (0.77 – 1.23)
Table A. Randomized controlled trials: effect of magnesium sulfate treatment for expected premature birth risk of
perinatal death or cerebral palsy (CP) 18
*36% of subjects were more than 4cm dilated and received only the loading dose.
In each trial, evaluators of perinatal outcomes were blinded to treatment and all outcomes were based on intention to
treat. ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulfate; BEAM, Beneficial Effects of Antenatal
Magnesium Sulfate; CI, confidence interval; MagNET, Magnesium and Neurologic Endpoints Trial; PTL, preterm
labor; RR, relative risk
The same conclusion was drawn by Conde-Agudelo et al., who used the same five RCT’s in their
systematic review in 2009, although the results were even better with both cerebral palsy (RR 0.69,
95% CI 0.55–0.88) and substantial gross motor dysfunction (RR 0.60, 95% CI, 0.43–0.83). 19
Although the neuroprotective mechanism of magnesium sulfate remains unclear, two main effects
are suggested: first, MgSO4 prevents glutamate binding with NMDA-receptors, which prevents the
calcium uptake into damaged neurons preventing apoptosis of those cells, respectively. Second,
magnesium is also suggested to serve as a vasoactive substance, which dilates cerebral arteries and
veins, thus reducing the risk of HIE. Furthermore, it seems that magnesium sulfate itself has a direct
anti-apoptotic effect on neurons. 20
7However, there is no definite evidence regarding minimum effective dose, optimal timing or
repeated use of magnesium sulfate regarding fetal neuroprotection.
1.3   Implementation of the New Guidelines
Several obstetrical societies have issued guidelines on MgS04 fetal neuroprotection but the
implementation has not been as easy as it was expected.
Bain et al. recently conducted a research considering the implementation of a new health care
guideline among doctors and nurses in Australia and New Zealand by one-to-one interviews with
health care professionals.21 The new guidelines were first published in 2010 in Australia and it was
anticipated that some sort of implementation would be required for the new guidelines to be put into
operation. The implementation project called WISH (Working to Improve Survival and Health for
babies born very preterm) was planned and taken into action. Today it offers large amount of useful
strategies to help with implementation and integration of a new guideline, to ensure the optimal
uptake of magnesium sulfate therapy for very and extremely preterm infants. The main barriers and
enablers in implementing a new guideline were associated mainly to theoretical domains. Education
of health care professionals and common knowledge were emphasized as well as the importance of
memory and attention, before coming into use routinely. The main barriers mentioned were related
to environmental context and resources. The use and knowledge of magnesium therapy seemed to
increase convincingly throughout the first three years of implementation.
Since preterm birth remains often very difficult to predict, it was suggested that pre-drawn syringes
should be taken into use as an enabler.21 More knowledge to predict a preterm labor such as
published in Raba et al. research is needed to help us target magnesium therapy in the future for
mothers who are in the highest risk to give birth in a very short period of time.4
There have been five publications on the magnesium sulfate implementation in the existing
literature22-26 and the implementation rate varied between 62 and 81.7%. However, these studies
included quite small number of patients (71-274).
1.4   Implementation of Magnesium Sulfate in Department of Obstetrics and Gynecology,
Helsinki University Central Hospital (HUCH)
The use of antenatal magnesium sulfate for fetal neuroprotection was launched in HUCH on June
7th, 2012. After careful examination of the literature and the current guidelines of the respectable
obstetrical societies, the proposal for the implementation was displayed to the hospital staff and
accepted by chief obstetricians and neonatologists.
The written guidelines were published at the hospital intranet. Midwives were briefed with special
attention, since the treatment execution is performed by midwives once the MgSO4 neuroprotection
has been commenced by attending obstetrician.
The upper gestational age for the pilot period of two months was chosen to be 29+6 weeks due to
the uncertainty of the population size and antenatal ward space sufficiency.
The eligible women were those with threatened or imminent preterm birth on ≤ 29+6 weeks of
gestation. “Imminent preterm birth” is defined as a high likelihood of birth due to one or both of the
following conditions: a) active labour with ≥ 2 cm of cervical dilation, with PPROM or intact
membranes, and b) a planned preterm birth for fetal or maternal indications on ≤ 29+6 weeks of
gestation.
8Contraindications for MgSO4 treatment are set to be: fetal lethal anomaly, maternal myasthenia
gravis or other neuromuscular disease, renal insufficiency, maternal of fetal distress with the need
for urgent delivery, and maternal refusal.
When fetal neuroprotection has been commenced by the attending obstetrician, two midwives
prepare the MgSO4 solutions (double check) and infuse a loading dose of 4-g within 30 minutes,
followed by maintenance dose of 2g/hour for 12 hours or until birth. Repeated doses were not
allowed if undelivered after the maintenance dose of 12 hours has been received. Maternal and fetal
follow-up during the MgSO4 treatment has been performed according to the existing guidelines.
After the pilot period of approximately two months, the implementation was evaluated and the
decision to set-up the upper gestational age of 31+6 weeks for the fetal neuroprotection has been
done (August 21st, 2012).
The data regarding the implementation of antenatal magnesium sulfate in 6/2012-12/2013 was
collected and analyzed by Ulla Isoranta in her graduation study in 2014.20
It was observed that only 79,4% of the mothers giving birth at less than 31+6 weeks of gestation in
HUCH Dept of Obstetrics and Gynecology received magnesium sulfate prior birth according to the
published international guidelines, mainly due to the lower gestational age upper limit in the pilot
phase of the MgSO4 implementation.20
2. Objective of research
Our main objective was to compare the implementation of antenatal magnesium sulfate for fetal
neuroprotection in HUCH Department of Obstetrics and Gynecology in 01/2014-06/2016, later
referred as period B with the previous published period, referred as period A.
We aimed also to identify patients that have not received magnesium sulfate despite of their
eligibility for the fetal neuroprotection.
The secondary outcome we have searched for were the proximity of the magnesium exposure to
delivery and the determination of the delivery-related blood loss in those that received MgSO4
compared to the cohort of the same gestational age that have not received MgSO4.
3. Patients and Methods
Pregnancy characteristics and fetal neuroprotection data were collected retrospectively and retrieved
from the hospital records. We have identified all deliveries ≤ 31+6 gestational weeks in both
periods A and B.
Women who gave birth in some other hospital, home or anywhere else outside of hospital were
excluded. To integrate the two implementation periods, some exclusions of patients were made
from period A raw data, resulting in minor changes.
Since fetal neuroprotection was introduced as a part of standard clinical care, no ethical permission
was necessary. The research permission was obtained by the HUCH Research Board, (extension of
the previous permission on the same issue, § 1, 9.1.2014 )
All data received were listed in an excel file for further analyzing. Analyzing was made with IBM
SPSS Statistics 24, Helsinki University license for 2017-2018, Chi-Square Test as a main statistic
test.
94. Results
The study population consists of 485 women, of which 180 were included on period A and 305 on
period B. On period A the total number of patients treated with MgS04 was 143 (79,4% of all births
≤ 31+6 gestational weeks) whereas on period B the number of women receiving fetal
neuroprotection was 263 (86,2% of all births ≤ 31+6 gestational weeks) (Figure 1). The overall
implementation on periods A and B was 83,7% (table B).
There were altogether 423 (87.2%) singleton pregnancies, 49 (10.1%) twin pregnancies, 2 (4.1%)
set of triplets and one quadriplet pregnancy (2.1%) with total of 531 fetuses. There were
188(38.8%) vaginal deliveries and 297 (61.2%) cesarean sections including elective, emergency and
crush cesareans.
Period A Period B Period A+B
Participants (N) 180 305 485
Gestational age, mean
(days)
200 202 201
MgSO4
implementation rate,
all patients (%)
79.4 86.2 83.7
MgSO4
implementation rate,
elective CS excluded
(%)
78.5 85.6 83.0
MgSO4 treatment
duration, mean (hours)
6.97 7.22 7.13
MgSO4 treatment, total
dose, mean (g)
17.13 17.90 17.61
MgSO4 full dose 28 g,
N (%)
56 (31.1) 80 (26.2) 136 (28)
MgS04 load + partial
dose, N (%)
84 (46.7) 167 (81.0) 251 (51.8)
MgSO4 load dose only,
N (%)
3 (1.7) 16 (5.2) 19 (3.9)
Blood loss volume,
patients treated with
MgSO4, mean (ml)
671.8 592.9 621.1
Blood loss volume,
patients not treated
with MgSO4, mean
(ml)
625.8 598.5 610.7
Table B. Main characteristics of the results in implementing new guidelines in Helsinki University Central Hospital
(HUCH) in period 2012-2016
abv. MgSO4 = magnesium sulfate; CS = Cesarean section
Although there was an increase of 8,6% on period B compared to period A (95% CI 0,995-1,184;
p = 0.057), the use of MgS04 for fetal neuroprotection has not reached statistical significance. The
number of women who did not receive magnesium although indicated was decreased by 33,0%
(95% CI 0,448-1,001).
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Figure 1. Number of women medicated with magnesium therapy on periods A and B.
Mean gestational age in periods A and B was 201 days (28+6 weeks). The mean duration of MgS04
administration on period B was 7,22 hours (p <0,001; 95% CI 6,65-7,80) and mean dose of
magnesium was 17,90 grams (p <0,001; 95% CI 16,66-19,14) (table B).  Compared to period one
there is a 4,5% increase in mean MgS04 dose.
There was a minor decrease in patients who received full dose of magnesium on period B. There are
also significant number of women who received almost a full dose of magnesium (28-g), but
because of miscalculated administration time the dose was only partial, p = 0,025 (Table B).
In some cases magnesium administration was ceased. The main reason for this was a need for
emergency cesarean section (CS) for maternal or fetal indication (39,9%). Almost one third (29,6%)
of all ceased magnesium administrations where ceased 30 minutes before a full administration of
twelve hours would have been reached without any specific reason.
No. of women (%)
Imminent delivery 52 (19,3)
Need for emergency
Cesarean section (within 30
minutes)
105 (38,9)
Maternal side effects* 14 (5,2)
Miscalculated time 80 (29,6)
Other reasons 19 (7,0)
Table C. Reasons for ceasing MgS04 administration
11
*Significant blood pressure drop, nausea, pain in cannulated arm, flushing symptoms and palpitations.
Other reasons: e.g. obstetrician´s orders, switch to oxytocine, fully dilated cervix, anuria, patients request.
The main reasons for not receiving MgS04 though indicated were rapid delivery (within 2h from
arrival to the hospital), a need for emergency CS (within 30 minutes) and a crash section (table D).
In 11patients there was no information on why magnesium wasn’t administered (2,3% of all).
During period A there were eight women (4,4%) with no information, whereas on period B there
were only three women (1,0%) with no information, with a total decrease of 77,9%.
Table D. Reasons for not receiving magnesium though indicated.
During period B as much as 35,4% of patients who received magnesium gave birth < 1 hour after
termination of MgS04 administration and a total of 55,9% gave birth < 6 hours after magnesium
treatment had ended (table E).
 Period A
N (%)
Period B
N (%)
Period A+B     N(%)
Time gap between
magnesium
administration and
birth
<6 hours 90 (62.9) 147 (55.9) 237 (58.4)
<12 hours 13 (9.1) 26 (9.9) 39 (9.6)
<24 hours 9 (6.3) 35 (13.3) 44 (10.8)
>24 hours 31 (21.7) 55 (20.9) 86 (21.2)
Total 143 (100.0) 263 (100.0) 406 (100.0)
Table E. Proximity of magnesium exposure to delivery, p = 0,168.
Comparison of the implementation rate in this study to other international published studies
(Table F).
No. of women (%)
Rapid delivery 17 (21,5)
Need for emergency
Cesarean section (within 30
minutes)
21 (26,6)
Crash Cesarean section 21 (26,6)
Contraindication 9 (11,4)
No information 11 (13,9)
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Table F. Comparing published international studies to the latest Finnish research of implementing a new
protocol.
No. = number; g = grams; i.v. = intravenous; h = hour
We collected the data of total blood loss during birth to see if there was any correlation between
magnesium administration and delivery-related blood loss in those that received MgSO4 compared
to those who did not receive MgSO4. Data of delivery-related blood loss in 14 women was missing.
Study
No. of
women
Uptake Repeated
dose
Regimen
Bouet, P.E. (2015) Implementation
of an antenatal magnesium sulfate
protocol for fetal neuroprotection in
preterm infants22
119 68.1% No ≤33 weeks of gestation
Load dose of 4g i.v. in 30
min
Administration 1g / h, max.
12 hours
Ow, L.L.et al. (2012) Feasibility of
implementing magnesium sulfate
for neuroprotection in
a tertiary obstetric unit23
168 73,2% Yes ≤32 weeks of gestation Load
dose of 4g i.v. in15 min.
Administration 2g / h,
reduced to 1g / h in the event
of significant maternal side
effects
Siwicki, K. et al. (2015) Nonreceipt
of antenatal magnesium sulfate for
fetal neuroprotection at
the Women’s and Children’s
Hospital, Adelaide 2010–201324
245 62,0% No 23+0 - 29+6 weeks of
gestation. Load dose of 4g
i.v..Administration 1g / h,
max. 24 hours
Tan, Y.H. et al. (2014) A
prospective audit of the adherence to
a new magnesium sulfate guideline
for the neuroprotection of infants
born less than 30 weeks' gestation 25
71 81,7% No 24+0 - 29+6 weeks of
gestation. Load dose of 4g
i.v. Administration 1g / h
Gibbins, K.J. (2013) Evaluation of
the clinical use of magnesium
sulfate for cerebral palsy prevention
26
274 71,9% No ≤32 weeks of gestation
Load dose of 6g i.v.
Administration of 2g / h
Mettänen, R. (2017)
Implementation of antenatal
magnesium sulfate for fetal
neuroprotection in the third-level
teaching university hospital; The
retrospective analysis in period
2012-2016
485 83,7% No ≤ 31+6 weeks of gestation
Load dose of 4g i.v. in 30
min
Administration 2g / h, max.
12 hours
13
There was no difference in the mean blood loss among the women who did received MgS04 for
fetal neuroprotection and those who did not received MgS04 (621.1 vas 610.7 ml) (Figure 2,Table
B).
Fig 2. Correlation between magnesium administration and total bleeding volume, periods A and B.
Mg = magnesium; ml = milliliters; y = yes; n = no
There was no correlation between total magnesium dose and bleeding volume, p = 0,48 or
magnesium administration and bleeding volume, p = 0,87. Instead a rather strong correlation
between delivery mode and blood loss was observed, p < 0,001.
14
5. Discussion
This research focused on the implementation rate of antenatal MgSO4 administration for fetal
neuroprotection during two periods, proximity of the MgSO4 exposure to delivery and the
comparison of blood loss among women with premature birth with and without administration of
MgSO4.
The overall implementation rate during both periods was 83,7%. The rate of 86.2% in period 2012-
2016 was higher than expected with an increase of 8,56% compared to the period A.
The implementation rate of full dose MgSO4 regimen (28g) of women with elective cesarean
section was almost 100%. We calculated the implementation rate by excluding those with elective
CS to determine the accurate implementation rate in those, whose delivery time was unpredictable.
We found the implementation rate of 83.0% as very successful and is higher than that in any of the
previous published study. Additionally, the number of pregnancies that received MgSO4 for the
fetal neuroprotection is the highest ever reported
Mean duration of magnesium administration was 7,13 hours and mean dose of MgSO4 was 17,61g.
In some cases magnesium was given not only for fetal neuroprotection but for pre-eclampsia too. In
those cases total magnesium dose was frequently more than the maximum dose (4g + 24g), but for
statistical analyzes those patients were considered as patients who received full dose of magnesium
(28g).
There was a decrease of 33% in women who did not receive magnesium sulfate even though
indicated from period A to period B. The decrease of 77,9% from period A to period B with those
who did not receive magnesium sulfate for an unknown reason is a huge accomplishment. A major
impact in decreasing the percentage of patients who did not receive magnesium though indicated
was an alteration in practice of administrating magnesium in emergency situations. During period
A, patients who gave birth relatively quickly upon admission or who gave birth by an emergency
CS within 30 minutes from decision did not generally receive magnesium even though there would
have been time for at least a loading dose administration. During period B there was an alteration in
the matter; patients were more often administrated at least a load dose (4g), were there no
contraindications and the predicted time preceding birth was estimated to be at least one hour.
The proximity of the magnesium exposure to delivery was also on a very satisfying level.
Altogether 68,0% of women gave birth <12 hours after the exposure to MgSO4 had ceased, and as
much as 58,4% delivered <6 hours after the exposure to magnesium. The data of those who
delivered <1 hour after the exposure to MgSO4 was collected only during period B being as high as
35,4%. Turitz et al. recently published a study of proximity of magnesium sulfate exposure to
neonatal outcomes. A strong association was noted between maternal exposure to magnesium
sulfate less than 12 hours before delivery and a significant decrease in CP, as compared with a
maternal exposure to magnesium sulfate >12 hours prior to delivery (OR 0,41; CI 95% 0,18-0,91;
p = 0,03).27 Hence we may conclude that the proximity of MgSO4 exposure to delivery in HUCH
has been at the “therapeutic” level.
McPherson et al. searched for a difference in fetal outcomes with different durations of magnesium
administration. Statistically there was no difference between duration of <12 hours, 12 to 18 hours
and more than 18 hours. They also found no evidence of greater fetal morbidity between the three
groups.28
15
The guidelines need constant updating, whilst midwives and gynecologist need regular audit and
feedback on hospital guidelines and new research data. It has been suggested that a higher
concentration of magnesium sulfate in fetuses may result in possible adverse effects, such as
necrotizing enterocolitis, intraventricular haemorrhage and increased mortality. Morag et al.
recently published a research, where magnesium concentration was measured of both mother and a
newborn infant after magnesium administration. They found that there was a remarkable correlation
(p = 0,001) between maternal magnesium concentration (mMgC) and infant magnesium
concentration (iMgC).29 Accordingly, higher or repeated doses of magnesium sulfate should be
considered only with extra caution.
We could not demonstrate any statistical and clinical difference in blood loss during delivery among
women with or without MgS04 administration which is in line with previous reports. However, a
strong correlation between mode of delivery and blood loss was noted, being higher in cesarean
deliveries, as expected.  The same conclusion was made by Sangkomkamhang et al. in their
research of mode of delivery and outcomes in preterm births.30
Our research data was collected retrospectively, out of obstetrical electronic patient data records.
Therefore the probability for an error is exclusively caused by handwork in collecting the data into
an Excel file.
The implementation rate and proximity of MgSO4 exposure to delivery were at a very high level
during both periods. Nevertheless, there is always something to improve. Detailed and explicitly
described guidelines of magnesium administration for fetal neuroprotection are written in
Haikarakansio, a Handbook of obstetric guidelines used by midwives and obstetricians in HUCH .
Therefore, there is no rational explanation why magnesium administration time was miscalculated
with 29,6% of those eligible for magnesium treatment (maintenance dose shorter 30 minutes). This
non-adherence to the local guidelines has been noted and an auditing with midwives will be made.
Fortunately, this miscalculation did not influence significantly total MgSO4 dose that fetuses
received.
Had the administration time been calculated correctly with every patient, the percentage of those
receiving full dose of magnesium could have been as high as 44,3%. Statistically there is a huge
difference between 26,2% and 44,3%. Certainly, there is only a small or no clinical difference
between the patients and the outcome of their prematurely born children with 27g or 28g dose28, but
guidelines do exist for a good reason and they are an outcome of many, long term researches
dealing with sufficient dose of magnesium sulfate in fetal neuroprotection.
In conclusion, MgSO4 administration for fetal neuroprotection has been successfully and safely
implemented in our institution. This is to our best knowledge the largest study with the highest
implementation rate ever reported.
Although not straightforward, taking into consideration the fact that the mean gestational age of our
cohort was 28+6 gestational weeks, with the NNT to prevent one CP in this group being 30, we
have theoretically prevented 17.7 CP cases (531 fetuses/30).
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